Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Loading...
Official URL
Full text at PDC
Publication date
2009
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Citations
Exportar
Citation
Javier Palazuelos, Tania Aguado, M. Ruth Pazos, Boris Julien, Carolina Carrasco, Eva Resel, Onintza Sagredo, Cristina Benito, Julián Romero, Iñigo Azcoitia, Javier Fernández-Ruiz, Manuel Guzmán, Ismael Galve-Roperh, Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity, Brain, Volume 132, Issue 11, November 2009, Pages 3152–3164,
Abstract
Cannabinoid-derived drugs are promising agents for the development of novel neuroprotective strategies. Activation of neuronal CB1 cannabinoid receptors attenuates excitotoxic glutamatergic neurotransmission, triggers prosurvival signalling pathways and palliates motor symptoms in animal models of neurodegenerative disorders. However, in Huntington's disease there is a very early downregulation of CB1 receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB1 receptor activation, foster the search for alternative pharmacological treatments. Here, we show that CB2 cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients. Genetic ablation of CB2 receptors in R6/2 mice, that express human mutant huntingtin exon 1, enhanced microglial activation, aggravated disease symptomatology and reduced mice lifespan. Likewise, induction of striatal excitotoxicity in CB2 receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration. Moreover, administration of CB2 receptor-selective agonists to wild-type mice subjected to excitotoxicity reduced neuroinflammation, brain oedema, striatal neuronal loss and motor symptoms. Studies on ganciclovir-induced depletion of astroglial proliferation in transgenic mice expressing thymidine kinase under the control of the glial fibrillary acidic protein promoter excluded the participation of proliferating astroglia in CB2 receptor-mediated actions. These findings support a pivotal role for CB2 receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington's disease as well as in other neurodegenerative disorders with a significant excitotoxic component.